Identification of Serum Biomarkers for CD15+ Hypodense Neutrophils in Severe Asthma

NCT02659618 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-02-11

No results posted yet for this study

Summary

The goal of this study is to identify a serum biomarker(s) that can detect increased levels of a population of CD15+ hypodense neutrophils termed low-density granulocytes (LDG) in the blood of patients with severe persistent asthma.

Conditions

  • Severe Persistent Asthma

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY
  • Rush University Medical Center

    lead OTHER

Eligibility

Min Age
12 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-09-26
Completion
2020-12-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02659618 on ClinicalTrials.gov